Aptar Pharma and Nanopharm Featured in ONdrugDelivery’s November 2019 Issue

Aptar Pharma is featured in the November 2019 edition of ONdrugDelivery magazine, which focuses on Pulmonary & Nasal Drug Delivery.

In this interesting article entitled “A Faster, More Cost-Effective Alternative to Generic Bioequivalence”, Dr. Jag Shur, CEO of Nanopharm, an Aptar Pharma company, explores the challenges companies face in bringing generic respiratory and nasal therapies to market amidst a changing regulatory landscape.  He explains the Aptar Pharma Services range for accelerating and derisking OINDP development, and introduces the CPhI 2019 Award winning SmartTrack as an alternative to bioequivalence studies.

Read the full article here.